Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis to Present at the Aegis Annual Growth Conference

GlobeNewswire September 19, 2016

Advaxis Unveils State-of-the-art Manufacturing Facility, Laboratory to Produce and Develop Novel Immuno-Oncology Therapeutics

GlobeNewswire September 12, 2016

N.J. Gov. Christie to Attend Advaxis Ribbon Cutting for New Manufacturing/Laboratory Facility in Princeton

GlobeNewswire September 8, 2016

Advaxis to Present at Rodman & Renshaw 18th Annual Global Investment Conference

GlobeNewswire September 6, 2016

Advaxis to Participate in Cervivor School

GlobeNewswire August 19, 2016

Advaxis Secures a $30M Direct Placement Financing to Healthcare Specialist Investors

GlobeNewswire August 16, 2016

Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage

GlobeNewswire August 11, 2016

Mid-Afternoon Market Update: Crude Oil Down 1.5%; RetailMeNot Shares Gain On Strong Results

Benzinga.com  August 2, 2016

18 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  August 2, 2016

Mid-Day Market Update: Dow Drops Over 100 Points; Avon Shares Surge Following Earnings Beat

Benzinga.com  August 2, 2016

Benzinga's Volume Movers

Benzinga.com  August 2, 2016

Mid-Morning Market Update: Markets Open Lower; Pfizer Tops Q2 Views

Benzinga.com  August 2, 2016

Collaboration Deal With Amgen Sends Advaxis Up 30%

Benzinga.com  August 2, 2016

It's Normal For Pfizer To Trade Down After Beating Estimates

Benzinga.com  August 2, 2016

Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort

GlobeNewswire July 26, 2016

Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients

GlobeNewswire July 21, 2016

European Medicines Agency Committee Classifies Advaxis’ Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product

GlobeNewswire July 18, 2016

Advaxis Appoints Ranya Dajani as Vice President, Corporate Development

GlobeNewswire July 12, 2016

Advaxis to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

GlobeNewswire July 8, 2016

FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer

GlobeNewswire July 6, 2016